PHARMA BULLETIN ⚕️

PHARMA UPDATES ⚕️
1.AstraZeneca gets European union approval for early lung cancer drug 
The approval was given based on good results from late stage trials which showed Tagrisso drug minimize risk of tumour growing back in cancer patient or death by 80%.
2.Bajaj Health care launched drug for Mucormycosis.
Company received nod from FDA India to Mfg. and market Posaconazole API for treating Black Fungus.
3.AstraZeneca and Abott cancel distribution aggrement for diabetes drug.
AstraZeneca India will continue to market Forxiga, Xigduo and Qtern.
4.Sun Pharma acquire rights to Trademark of 3 diabetes drug brand in India from AstraZeneca.
Sun Pharma acquire rights of trademark of Oxra, Oxramet and Oxraduo in India from AstraZeneca Pharma India Ltd. Parent Company.
5.Glenegels global health city Hospital collaborate with Cipla for Covid drug.
Both collaborated to launch Roches's Antibody drug Cocktail for early stage Covid treatment in Chennai.
6.ARTPark launch X-ray Setu platform for easy Covid intervention.
Free use platform take few seconds to interpret chest X-ray with 98.26% Sensitivity towards Covid.

Comments

Post a Comment

Popular posts from this blog

PHARMA BULLETIN ⚕️

Image
PHARMA UPDATES ⚕️ 1.Zydus vaccine for children above 12 years could be available by August. National technical advisory board group of Immunisation ( NTAGI ) chairman Dr Arora also added that the trials are likely to be Completed by the end of next month. 2.India achieve milestone of conducting 40 crores Covid sample testing. India has tested 40,18,11,892 samples across the nation till 25 June 2021 The Indian council of Medical Research said. 251 doctors Challenge Govt. FIR Diktat. -Ahmedabad: A group of 251 graduate students and super-specialists practicing in Gujarat approach the Gujarat High Court to challenge the decision of the state government to join Covid-19’s obligations and call for obligations. I submitted a FIR as not responding. 4. Serum institute of India produce more than 10 crore Doses of covishield in June. The Drugs Controller General of India (DCGI) on Sunday said that the Serum Institute of India has produced 10 crore
Read more

PHARMA BULLETIN ⚕️

Image
PHARMA UPDATES ⚕️ 1. Covid 19 Vaccine effective for at least 1 year :- Karnataka Virologist. Karnataka based Virologist Dr V Ravi said that available evidence suggests that vaccinated person would get protection for two to three years If more troubling Variants don't emerge. 2.Indian Immunologicals to begin Drug substance production for Covaxin from June. Indian Immunological Limited has announced it's plan to start the production of drug substance for Covaxin From June and Despatch the first Batch to Bharat Biotech by July. 3. Zydus Cadilla plans test for its Covid Vaccine in 5 to 12 years age group. Zydus Cadilla is planning to start Clinical trials of its Covid Vaccine, ZycoV-D, in children of 5 to 12 years age group. 4. Modern laboratories to mfg. Amphotericin B. Amphotericin B is Used for treatment of Black Fungus, White Fungus and Yellow Fungus. 5.IIT Hyderabad researchers develop oral an solution to treat black
Read more

PHARMA BULLETIN⚕️

Image
PHARMA UPDATES ⚕️ 1.BDR Pharma launches drug to treat advances tage Ovarian and Prostate Cancer. BDR Pharma has launched Rucaparib under brand name BDPARIB. It first affordable drug treat Ovarian and Prostate Cancer. 2.Seeking Pills to cure Covid Pharma Companies eye alternative to vaccine. Many drug makers are working on so called oral antivirals which would copy what drug Tamiflu does for Influenza. 3.Lupin gets $50 Million from Boehringer for anticancer drug. Lupin has received payment of around Rs.363.5 Crore from Boehringer Ingelheim for achievement of key milestones by its cancer drug potential drug therapy for cancer patients. 4.Agrrement signed b/w Bharat Biotech Gujarat Covid Vaccine Consortium. Memorandum of understanding (MoU) has signed b/w Bharat Biotech and Gujarat Covid Vaccine Consortium for contract Mfg.drug substance for Covaxin. 5.Zydus Cadilla has sought drugs Controller General of India (DCGI)  Approval to
Read more